History of Vaccination and Disease Eradication

The history of vaccination and disease eradication chronicles the scientific transition from empirical variolation to rational vaccine engineering and coordinated global epidemiology. Across three centuries, active immunization has evolved from cutaneous inoculation with uncharacterized poxvirus lesions into molecularly defined platforms encompassing live-attenuated and whole-inactivated vaccines, toxoid and polysaccharide-protein conjugate vaccines, recombinant subunit and virus-like particle vaccines, and mRNA vaccines.

By establishing durable antibody and cellular memory before pathogen exposure, vaccination has prevented hundreds of millions of deaths, increased global life expectancy, and achieved the permanent biological extinction of two major infectious pathogens in nature: human smallpox (Variola major and Variola minor, certified eradicated in 1980) and cattle rinderpest (Morbillivirus, certified eradicated in 2011).

Pre-Jennerian Variolation in Asia, Africa, and Colonial Boston

Centuries before the discovery of viruses or adaptive immunology, physicians and traditional healers observed that survivors of smallpox acquired lifelong resistance to reinfection. By the 10th to 16th centuries in Song and Ming Dynasty China, practitioners practiced variolation via nasal insufflation, blowing powdered scabs harvested from mild Variola major cases into the nostrils of susceptible children. In the Ottoman Empire, West Africa, and South Asia, cutaneous variolation was performed by lancing the skin and introducing fluid from a smallpox pustule.

In 1721, Lady Mary Wortley Montagu, who had witnessed variolation in Constantinople and had her own children inoculated, introduced the procedure to British royal physicians. Simultaneously, during the 1721 Boston smallpox epidemic, Onesimus—an enslaved West African man who described how dermal inoculation had protected him in Africa—shared the technique with Puritan minister Cotton Mather. Physician Zabdiel Boylston variolated 248 residents across Boston; biostatistical records compiled by Mather and Boylston demonstrated a case fatality rate of 2.0% (6 deaths among 298 total variolated individuals) compared to 14.8% (844 deaths among 5,759 cases) in naturally acquired smallpox. Despite this sevenfold reduction in mortality, variolated subjects shed infectious Variola major and could seed secondary outbreaks.

Edward Jenner, Cowpox Cross-Protection, and Louis Pasteur's Attenuation

In rural Gloucestershire, English physician Edward Jenner investigated the epidemiological observation that dairymaids who contracted cowpox—a mild vesicular infection of cattle udders caused by a zoonotic Orthopoxvirus—remained refractory to smallpox. On May 14, 1796, Jenner inoculated eight-year-old James Phipps with fluid taken from a cowpox lesion on the hand of dairymaid Sarah Nelmes. Six weeks later, on July 1, 1796, Jenner challenged Phipps by inoculating both arms with fresh Variola major pus; no disease developed. Jenner published his 23 case studies in An Inquiry into the Causes and Effects of the Variolae Vaccinae (1798), coining the term vaccination (from Latin vacca, cow). Conserved cross-reactive surface proteins shared across orthopoxviruses allowed heterotypic cowpox and vaccinia viruses to elicit neutralizing antibodies without risking Variola transmission. Between 1803 and 1806, King Charles IV of Spain sponsored the Balmis Royal Philanthropic Vaccine Expedition, led by Francisco Javier de Balmis and nurse Isabel Zendal, which transported live vaccinia virus across the Atlantic and Pacific oceans via arm-to-arm transfer in 22 orphaned children to immunize populations across the Americas and Asia.

Nearly a century later, French chemist and microbiologist Louis Pasteur established that virulence is not an immutable property of a microbe, formulating the principle of rational pathogen attenuation. In 1879, Pasteur discovered that aging cultures of Pasteurella multocida (the agent of fowl cholera) under atmospheric O₂ rendered the bacteria non-lethal while preserving protective immunogenicity in chickens. In May 1881, at a public trial in Pouilly-le-Fort, Pasteur immunized 25 sheep with Bacillus anthracis attenuated at 42–43 °C with potassium dichromate (K₂Cr₂O₇); upon lethal anthrax challenge, all 25 vaccinated sheep survived while all 25 unvaccinated control sheep died. In 1885, collaborating with Émile Roux, Pasteur attenuated rabies virus through serial passage in rabbits followed by progressive KOH desiccation of harvested spinal cords, successfully administering post-exposure prophylaxis to nine-year-old Joseph Meister on July 6, 1885, after the boy had been mauled by a rabid dog.

Toxoids, BCG, Yellow Fever 17D, and Enders's Cell-Culture Revolution

Following Emil von Behring and Shibasaburō Kitasato's 1890 discovery of passive serum antitoxins (awarded the first Nobel Prize in Physiology or Medicine in 1901), Gaston Ramon at the Institut Pasteur discovered in 1923 that treating diphtheria and tetanus exotoxins with 0.4% formaldehyde (HCHO) at 37 °C yielded non-toxic toxoids (anatoxins) that induced active humoral immunity. Meanwhile, Albert Calmette and Camille Guérin passaged virulent Mycobacterium bovis 230 times over 13 years (1908–1921) on potato slices soaked in ox-bile glycerol to generate Bacillus Calmette-Guérin (BCG) against tuberculosis. In 1937, Max Theiler and Hugh Smith passaged the virulent Asibi strain of yellow fever virus through mouse embryonic tissue and minced chick embryos lacking nervous tissue for 176 passages to derive the live-attenuated 17D yellow fever vaccine, earning Theiler the 1951 Nobel Prize.

A technical barrier remained for human viral vaccines: propagating viruses outside whole animals or neural tissue (which risked allergic encephalomyelitis). In 1949, John Enders, Thomas Weller, and Frederick Robbins demonstrated that poliovirus could be propagated to high titers in in vitro cultures of non-neural human embryonic skin, muscle, and kidney cells (awarded the 1954 Nobel Prize). Cell culture immediately unlocked the modern era of viral vaccinology:

• Jonas Salk (1954): Propagated poliovirus types 1, 2, and 3 in monkey kidney cells and inactivated the virions with 1:4,000 formalin to produce the injectable Inactivated Polio Vaccine (IPV), validated in the 1954 Francis Field Trial across 1.8 million children.
• Albert Sabin (1961): Selected neurovirulence-attenuated poliovirus mutants by serial passage at sub-physiological temperatures to create the trivalent Oral Polio Vaccine (OPV), which induced intestinal secretory IgA to block fecal-oral transmission.
• Maurice Hilleman (1950s–1980s): Leading vaccine research at Merck, Hilleman developed over 40 experimental and licensed vaccines—including eight of the fourteen vaccines on routine pediatric schedules: measles (Moraten strain), mumps (Jeryl Lynn strain, isolated from his daughter's throat in 1963), rubella (Wistar RA 27/3, combined into MMR in 1971), Hepatitis A, the first yeast-derived recombinant subunit Hepatitis B vaccine, Haemophilus influenzae type b (Hib) conjugate, pneumococcal, meningococcal, and varicella vaccines—an output estimated to save ~8 million human lives every year.

The WHO Smallpox Eradication Campaign and Ring Vaccination

In epidemiologic nomenclature, control reduces disease incidence to locally acceptable levels, elimination reduces transmission of a pathogen to zero within a defined geographic region (requiring continued interventions to prevent re-establishment), and eradication permanently reduces the worldwide incidence of an infection to zero in nature as a result of deliberate efforts.

In 1958, Soviet Deputy Minister of Health Viktor Zhdanov proposed the global eradication of smallpox to the World Health Assembly. When the World Health Organization (WHO) launched the Intensified Smallpox Eradication Programme in 1967 under the direction of D. A. Henderson, smallpox remained endemic in 31 countries, causing 10 to 15 million cases and ~2 million deaths annually. Three technological and strategic innovations enabled eradication despite incomplete mass vaccination coverage in resource-limited regions:

1. Thermostable Freeze-Dried Vaccine (Leslie Collier): A peptone-stabilized lyophilized vaccinia formulation that maintained potency for >4 weeks at 37 °C in tropical climates without a cold chain.
2. The Bifurcated Needle (Benjamin Rubin, 1965): A two-pronged sewing-machine needle engineered at Wyeth that held 0.0025 mL of reconstituted vaccine by capillary action—requiring one-fourth the viral dose of conventional scarification, allowing rapid boiling sterilization, and enabling trained villagers to perform 15 rapid percutaneous punctures into the epidermis.
3. Surveillance and Containment (Ring Vaccination): Pioneered in West Africa by William Foege during a vaccine shortage in eastern Nigeria in 1966, epidemiological teams shifted from attempting 100% population-wide vaccination to rapid case detection, isolation of the index patient, vaccination of all household and village contacts (the primary ring), and vaccination of contacts-of-contacts (the secondary ring). Because the Vaccinia vaccine induces protective immunity within 3–4 days—substantially faster than the 12- to 14-day incubation period of Variola major—ring vaccination surrounded every outbreak with an impenetrable barrier of immune hosts.

The last naturally acquired case of virulent Variola major occurred in three-year-old Rahima Banu in Bangladesh in October 1975, and the last natural case of Variola minor occurred in hospital cook Ali Maow Maalin in Merca, Somalia, on October 26, 1977. On May 8, 1980, the Thirty-Third World Health Assembly certified the global eradication of smallpox. In 2011, the Food and Agriculture Organization (FAO) and World Organisation for Animal Health (WOAH) certified the eradication of rinderpest, a devastating cattle morbillivirus, using Walter Plowright's tissue-culture attenuated vaccine.

Four Biological Prerequisites and Ongoing Eradication Campaigns

Smallpox and rinderpest satisfied four strict biological and epidemiological criteria required for global eradication:

1. Absence of a Non-Human or Environmental Reservoir: Variola infects only humans; once human-to-human transmission chains are broken, the virus cannot re-emerge from wildlife, soil, or arthropod vectors (unlike yellow fever, rabies, or tetanus).
2. Absence of Chronic Subclinical Carriers: Every infectious case of smallpox manifested visible centrifugal vesiculopustular rash (unlike latent tuberculosis, herpesviruses, or asymptomatic poliomyelitis where 99% of infections are subclinical), allowing field surveillance teams to identify transmission nodes visually using symptom recognition cards.
3. Antigenic Stability and Lifelong Immunity: Variola existed as a single stable antigenic serotype with a low double-stranded DNA mutation rate, and a single vaccination or natural infection conferred multi-decade sterilizing immunity.
4. Moderate Basic Reproduction Number (R₀ ≈ 3.5 to 6.0): Corresponding to a herd immunity threshold of 71% to 83%, lower than that of measles (R₀ ≈ 12 to 18).

Currently, two human pathogens are targeted by active global eradication campaigns: Poliomyelitis (reduced by >99.9% since 1988, with Wild Poliovirus Type 2 certified eradicated in 2015, Type 3 certified eradicated in 2019, and endemic Wild Poliovirus Type 1 restricted to pockets of Pakistan and Afghanistan, alongside deployment of genetically stabilized nOPV2 to halt circulating vaccine-derived polioviruses) and Dracunculiasis (Guinea worm disease, Dracunculus medinensis, reduced from 3.5 million cases in 1986 to fewer than 15 annual human cases via water filtration and vector control).

Why did variolation carry a higher epidemiological risk than Jennerian vaccination?

Variolation inoculated susceptible individuals with live, unattenuated Variola major virus harvested from human smallpox scabs or pustules. Although cutaneous inoculation reduced the individual case fatality rate from ~14.8% (in respiratory transmission) to ~2.0%, variolated individuals developed systemic viral replication and shed infectious Variola virions from respiratory secretions and skin lesions, frequently igniting severe smallpox epidemics in surrounding unvaccinated communities. Edward Jenner's Orthopoxvirus vaccine induced cross-reactive neutralizing antibodies against conserved poxvirus envelope proteins while remaining non-transmissible and non-lethal in immunocompetent humans.

How did ring vaccination overcome low baseline vaccination coverage during the Smallpox Eradication Programme?

Rather than attempting to vaccinate 100% of the global population simultaneously, surveillance-and-containment (ring vaccination) exploited the network topology of Variola transmission and its 12- to 14-day incubation window. Field teams rapidly identified each symptomatic index case and vaccinated all close contacts and contacts-of-contacts within a several-kilometer radius. Because percutaneous Vaccinia inoculation generates neutralizing immunity within 3 to 4 days, post-exposure ring vaccination aborted incubation in exposed contacts and deprived the virus of susceptible secondary hosts.

Why can tetanus never be eradicated despite the existence of a near-100% effective toxoid vaccine?

Global disease eradication requires that the causative pathogen replicate exclusively in humans without an independent environmental or animal reservoir. Tetanus is caused by the neurotoxin tetanospasmin produced by Clostridium tetani, an obligate anaerobic, spore-forming bacillus ubiquitous in agricultural soil, dust, and mammalian gastrointestinal tracts worldwide. Because metabolically dormant C. tetani endospores survive in soil for decades and infection is acquired directly from contaminated wounds rather than human-to-human transmission, herd immunity does not apply and continuous individual vaccination is required.

1. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z., & Ladnyi, I. D. (1988). Smallpox and its Eradication. World Health Organization. https://iris.who.int/handle/10665/39485
2. Plotkin, S. A. (2014). History of vaccination. Proceedings of the National Academy of Sciences, 111(34), 12283–12287. https://doi.org/10.1073/pnas.1400472111
3. Enders, J. F., Weller, T. H., & Robbins, F. C. (1949). Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science, 109(2822), 85–87. https://doi.org/10.1126/science.109.2822.85
4. Greenwood, B. (2014). The contribution of vaccination to global health: Past, present and future. Philosophical Transactions of the Royal Society B: Biological Sciences, 369(1645), 20130433. https://doi.org/10.1098/rstb.2013.0433